Pharmaceutical Executive July 9, 2024
Jon Koch

Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.

Recently, more than 4,000 people from across the globe gathered in Atlanta to address the latest methodologies, data analytics, and evidence-based approaches that drive transformative change. The conference was held by ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR). One organization in attendance was Avalere Health, a global commercialization firm that partners with stakeholders across the healthcare ecosystem to provide a variety of services, including market access and HEOR. The following is Avalere Health’s global CEO’s perspective on...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), Big Data, Conferences / Podcast, Patient / Consumer, Provider, Technology, Trends
Related Articles:
The case for human-centered AI
European Commission Approves Nvidia’s Proposed Acquisition of Run:ai
How Health Systems Can Collaborate on AI Tools
The Future Talent Equation: How To Identify And Retain Talent In The Age Of AI
A Roadmap For AI In Education: Turning Disruption Into Opportunity

Share This Article